Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)

4 clinical trials · Condition

Record	Firm	Date
A Study of Evaluating the Safety and Efficacy of ATG-010 in Relapsed/Refractory Diffuse Large B-Cell Lymphoma (NCT03992339)	Antengene Corporation	2020-04-09
Study of Effectiveness of Axicabtagene Ciloleucel Compared to Standard of Care Therapy in Patients With Relapsed/Refractory Diffuse Large B Cell Lymphoma (NCT03391466)	Kite, A Gilead Company	2018-01-25
Cluster of Differentiation Antigen 19/22(CD19/22) CAR T Cells (AUTO3) for the Treatment of Diffuse Large B Cell Lymphoma (NCT03287817)	Autolus Limited	2017-09-05

Every clearance here is in the API, with alerts when new ones post.